Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
04. November 2024 07:30 ET | Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
enteralogo.png
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
26. März 2024 08:30 ET | Entera Bio Ltd.
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
RactigenLogo.png
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
02. November 2023 08:00 ET | Ractigen Therapeutics
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
enteralogo.png
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
10. November 2022 16:15 ET | Entera Bio Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
enteralogo.png
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
21. September 2022 08:30 ET | Entera Bio Ltd.
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today...
enteralogo.png
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
18. Juli 2022 07:05 ET | Entera Bio Ltd.
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the...
univest-logo.png
Univest Securities, LLC Announces Closing of $25 Million IPO for its Client Zhong Yang Financial Group Limited (Nasdaq: TOP)
03. Juni 2022 17:00 ET | Univest Securities, LLC
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,...
BMD Adds TAMKO’s Envision Decking in Southern California
31. Januar 2019 09:00 ET | TAMKO Building Products, Inc.
JOPLIN, MISSOURI, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Building Materials Distributors, Inc. (BMD) is now distributing TAMKO Building Products, Inc.’s Envision® composite decking in southern...